Weihai Disu Pharmaceutical

Established in 2005;

A subsidiary of Disha Group;

Specialized in APIs and intermediates;

Two manufacturing sites: Qilu Plant & Gushan Plant;

Performs strictly to the standards of CP, JP, EP and USP;

National high-tech enterprise with R&D, production and sale of APIs and intermediates.

Research and Development

State Accredited Enterprise Technical Center, with academician workstation and post-doctoral workstation;

Over 300 researchers ( including 15 doctors and nearly 200 masters);

More than 1000 advanced researching instruments;

Powerful researching strength in new products;

Employees in R&D department:

180 for synthesis,

60 for formulation,

60 for analysis.

170 new products are under research;

Including:

Formulations, APIs, intermediates, veterinary drugs, marine bio-products;

Class I new drug:

7903, Chemical anti-epileptic drug with 4 approved and the other 11 patents;

F12901, Chemical drug, used to treat anti-hypertension, with proprietary intellectual property rights.

LIQ, Herbal drug, used to treat coronary heart disease and palpitate;

Signed a strategic cooperation agreement with the Chinese Academy of Sciences (Shanghai Institute of Materia Medica), to carry out extensive cooperation projects and personnel training;

Established a long-term cooperative relationship with Peking University, Fudan University, Shanghai Jiao Tong University, Shandong University and other dozens of domestic research institutes and universities.

Exported Products:

APIs: Flunarizine HCl, Candesartan cilexetil, Glipizide, Bupropion HCl, Alogliptin, Roflumilast, etc.

Intermediates: of Oxybutynin, of Telmisartan, etc